Physiologix™ SF and NB-ROC™ Show Enhanced T-Cell Transduction Efficiency

16 May 2023
Poster About Physiologix Serum Replacement & NB-ROC T-Cell Culture Media Combination

Physiologix™ Serum Replacement and NB-ROC™ T-Cell Culture Media Combination Shows Enhanced T-Cell Transduction Efficiency for CAR-T Therapy

CD19 chimeric antigen receptor (CAR) T-cell therapy has shown a great potential for the treatment of B-cell malignancies and lymphoma, and an increased number of studies are in progress for its translation to solid tumors (1,2). Success of this treatment is unfortunately limited by multiple factors such as donor-to-donor variability, patients’ response to the therapy, and manufacturing related issues. Cell culture media is a critical factor to consider when improving the process as it is intimately linked to cell function and metabolism (3). In this study, we tested a new cell culture media, NB-ROC™, developed specifically to support activated T-cell proliferation and lentivirus transduction. Based on our previous data generated with the University of Pennsylvania on T cells, we supplemented NB-ROC with 2% Physiologix™ XF (human growth factor concentrate), a cGMP, xeno-free media supplement made for stem cells and T cells that can replace standard serum supplements such as FBS and human serum.

Poster as presented at American Society of Gene and Cell Therapy (ASGCT)’s 2023 annual meeting

Nucleus Detailed Report Diagram Compared to CTS™ OpTmizer T-cell expansion supplemented with 5% human serum, NB-ROC shows on a Dynabeads-activated T cell model a maintained proliferation rate and population doubling (Figures A and B) with a preserved phenotype – determined through the evaluation of surface expression markers such as PD-1, CCR-7, and CD45RO (data not shown) over a period of 7 days. Lentivirus transduction data is more compelling as it shows an increased level by 20-30% compared to OpTmizer supplemented with human serum (Figures C and D). Our data also confirms previous observations on Physiologix, as supplementing CTS OpTmizer with 2% Physiologix shows significant transduction efficiency improvement compared to when it is supplemented with 5% human serum. All in all, our data show that NB-ROC, as a serum free media, combined with Physiologix offers a very promising alternative for an improved T-cell transduction efficiency with a maintained phenotype and proliferation rate on both 6 well plate and G-Rex model. This set of data holds the promise for enhancing transduction efficiency for CAR-T therapy which will help ameliorate the process and bring more success to the field.

For more information on NB-ROC SF T Cell Media, please visit the product page here.

For more information on Physiologix, please visit the product page here.

Download Guide

Share this article

Brad N. Taylor, Ph.D.
Dr. Brad Taylor has 17 years of experience commercializing products for scientists in both academia and industry before joining Nucleus Biologics. Most recently, Dr. Taylor was the Director of Global Marketing at HemaCare, supporting the needs of the cellular therapy industry. Prior to HemaCare, Dr. Taylor spent 11 years at PerkinElmer supporting in vivo imaging platforms and has held leadership roles in technical support, product management, and marketing. Dr. Taylor holds a M.S. in Microbiology and Immunology from Louisiana State University Health Sciences Center and a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany.